Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Carboplatin/Etoposide in ES-SCLC
NCT07057791Phase 2Recruiting
- Sponsor
- PrECOG
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in small cell lung cancer (SCLC), sponsored by PrECOG. Started Mar 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07057791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057791.